The heparin market involves pharmaceutical companies, healthcare institutions, distributors, and other stakeholders engaged in the production, distribution, and utilization of heparin products. The market is influenced by factors such as regulatory approvals, research and development activities, healthcare expenditure, and the prevalence of conditions requiring anticoagulant therapy. Heparin is commonly used to prevent and treat conditions characterized by abnormal blood clotting, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and other thromboembolic events. Heparin is administered before and after certain surgical procedures to reduce the risk of blood clot formation. It is particularly common in surgeries involving blood vessels and the heart.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/europe-and-middle-east-heparin-market
The Europe and Middle East Heparin Market is expected to reach USD 3,794,707.94 thousand by 2031 from USD 2,444,237.28 thousand in 2024, growing at a CAGR of 5.7% in the forecast period of 2024 to 2031.
Key Findings of the Study
Rise Increasing Research and Development Activities
Ongoing R&D efforts lead to the development of innovative dosage forms, such as extended-release formulations or alternative administration routes (oral formulations). These innovations can improve patient compliance and expand the range of therapeutic options. Researchers focus on optimizing the molecular structures of heparin to enhance its efficacy while minimizing side effects and risks. Modifications may lead to heparin variants with improved pharmacokinetics and safety profiles. R&D activities aim to create heparin derivatives with specific targeting capabilities. Tailoring heparin to interact with specific biological targets can result in therapies that are more precise and have reduced off-target effects. R&D activities seek to uncover additional therapeutic applications for heparin beyond its traditional use as an anticoagulant. This could include exploring its potential in treating inflammatory disorders, cancer, or other conditions.
The continuous drive for innovation, expanded therapeutic applications, and improved manufacturing processes contribute to the evolution of heparin-based therapies, providing healthcare professionals and patients with advanced and effective treatment options. Regular monitoring of research advancements and clinical developments is essential for a comprehensive understanding of the evolving heparin market landscape. Rising research and development activities play a pivotal role in driving the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Product Type (Low Molecular Weight Heparin (LMWH) and Unfractionated Heparin), Mode of Administration (Subcutaneous, Intravenous, and Others), Packaging (10000 Unit, 25000 Unit, 5000 Unit, 1000 Unit, 100 Unit, 10 Unit, and Others), Source (Biological and Synthetic), Indication (Deep Vein Thrombosis, Pulmonary Embolism, Peripheral Artery Disease, Arterial thromboembolism, Myocardial Infarction, Atrial Fibrillation, and Others), Type (Generics and Branded), Container Type (Vials, Bags, Bottles, and Others), Packaging Material (Glass and Plastic), End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Drug Store, Online Pharmacy, and Others)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Switzerland, Austria, Poland, Turkey, Belgium, Malta, Romania, Czech Republic, Ireland, Portugal, Norway, Greece, Bulgaria, Slovakia, Cyprus, Estonia, Latvia, Croatia, Bosnia & Herzegovina, Rest of Europe, and Saudi Arabia
|
|
Market Players Covered
|
LABORATORIOS FARMACEUTICOS ROVI SA (Spain), ITALFARMACO S.p.A. (Italy), Sanofi (France), Leo pharma A/S (Denmark),Merck KGaA (U.S) , Bioiberica S.A.U(Spain), Opocrin S.p.A. (Italy), and Eisai Co. (Japan), Ltd, and Hepac (Netherlands) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand
|
Segment Analysis
The Europe and Middle East heparin market is segmented into ten notable segments based on product type, mode of administration, packaging, source, indication, type, container type, packaging material, end user, and distribution channel.
- On the basis of product type, the market is segmented into Low Molecular Weight Heparin (LMWH) and unfractionated heparin
In 2024, the Low Molecular Weight Heparin (LMWH) segment is expected to dominate the market
In 2024, the Low Molecular Weight Heparin (LMWH) segment is expected to dominate the market with a market share of 77.83% due to growing awareness regarding the benefits of heparin.
- On the basis of mode of administration, the market is segmented into subcutaneous, intravenous, and others
In 2024, the subcutaneous segment is expected to dominate the market
In 2024, the subcutaneous segment is expected to dominate the market with a market share of 77.87% due to its rising prevalence among population.
- On the basis of packaging, the market is segmented into 10000 unit, 25000 unit, 5000 unit, 1000 unit, 100 unit, 10 unit, and others. In 2024, the 10000 unit segment is expected to dominate the market with a market share of 31.32%
- On the basis of source, the market is segmented into biological and synthetic. In 2024, the biological segment is expected to dominate the market with a market share of 92.20%
- On the basis of indication, the market is segmented into deep vein thrombosis, pulmonary embolism, peripheral artery disease, arterial thromboembolism, myocardial infarction, atrial fibrillation, and others. In 2024, the deep vein thrombosis segment is expected to dominate the market with a market share of 55.38%
- On the basis of type, the market is segmented into generics and branded. In 2024, the generics segment is expected to dominate the market with a market share of 66.93%
- On the basis of container type, the market is segmented into vials, bags, bottles, and others. In 2024, the vials segment is expected to dominate the market with a market share of 41.53%
- On the basis of packaging material, the market is segmented into glass and plastic. In 2024, the glass segment is expected to dominate the market with a market share of 68.59%
- On the basis of end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, homecare, and others. In 2024, the hospitals segment is expected to dominate the market with a market share of 61.34%
- On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy & drug store, online pharmacy, and others. In 2024, the hospital pharmacy segment is expected to dominate the market with a market share of 65.74%
Major Players
Data Bridge Market Research analyzes LABORATORIOS FARMACEUTICOS ROVI SA (Spain), ITALFARMACO S.p.A. (Italy), Sanofi (France), Leo pharma A/S (Denmark), and Merck KGaA (U.S) as the major market players operating in the Europe and Middle East heparin market.
Market Developments
- In December 2023, Eisai Co., Ltd. launched a computer program that can predict the buildup of a substance called amyloid beta in the brain using a wristband sensor. This prediction is crucial for understanding Alzheimer's disease by collecting information about patient’s daily habits and body. This program can help the company to identify potential issues related to Alzheimer's disease without complicated tests
- In August 2023, LABORATORIOS FARMACEUTICOS ROVI SA got the best ranking in the pharmaceutical industry category in the world. It was rated on environmental, social and corporate governance (ESG) risks drawn up by Sustainalytics, a leading independent ESG research, rating and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies and helps the company to grow more efficiency
- In April 2023, LABORATORIOS FARMACEUTICOS ROVI SA developed a chair to examine the psychological implications and advantages of technology in the prevention of mental health issues. The goal is to contribute to the enhancement of societal mental and the company growth by harnessing the potential of new technologies, thereby elevating the level of care accessible to individual
- In October 2022, Opocrin S.p.A. acquired Omikron Italia S.r.l. Hence, Opocrin S.p.A. becomes the main shareholders of Omikron Italia S.r.l., a pharmaceutical company that develops innovative therapeutic solutions for vascular and ophthalmic pathologies. This helped the company to strengthen its product portfolio
- In June 2019, Bioiberica's Business Unit participated in DCAT 2019 with the objective of establishing strategic alliances and find new business opportunities in the US market. It helped the company grow in the market by developing alliances
Regional Analysis
Geographically, the countries covered in the market report are Germany, France, U.K., Italy, Spain, Switzerland, Austria, Poland, Turkey, Belgium, Malta, Romania, Czech Republic, Ireland, Portugal, Norway, Greece, Bulgaria, Slovakia, Cyprus, Estonia, Latvia, Croatia, Bosnia & Herzegovina, rest of Europe, and Saudi Arabia.
As per Data Bridge Market Research analysis:
Germany is the dominant and the fastest-growing country in the Europe and Middle East heparin market
Germany is expected to dominate the market due to rising prevalence of venous thromboembolism and pulmonary embolism. It is also due to increasing demand for enhanced crop traits, improved agricultural productivity, and advancements in genetic engineering technologies.
For more detailed information about the Europe and Middle East heparin market report, click here – https://www.databridgemarketresearch.com/jp/reports/europe-and-middle-east-heparin-market
